ストックスクリーナーアプリを入手
22.82
7.84%
1.66
アフターアワーズ：
22.50
-0.32
-1.40%
前日終値:
$21.16
開ける：
$20.97
24時間の取引高:
3.55M
Relative Volume:
1.16
時価総額：
$1.44B
収益：
$16.10M
当期純損益:
$-198.97M
株価収益率:
-6.5558
EPS:
-3.4809
ネットキャッシュフロー:
$-183.99M
1週間 パフォーマンス:
+36.40%
1か月 パフォーマンス:
+31.22%
6か月 パフォーマンス:
-17.05%
1年 パフォーマンス:
+98.78%
1日の値動き範囲:
$20.50
$23.17
1週間の範囲:
$17.65
$23.17
52週間の値動き範囲:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Compare QURE vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
22.82 | 1.33B | 16.10M | -198.97M | -183.99M | -3.4809 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-11 | アップグレード | Mizuho | Neutral → Outperform |
| 2026-03-09 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | ダウングレード | Mizuho | Outperform → Neutral |
| 2026-03-03 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | 開始されました | Wolfe Research | Peer Perform |
| 2026-01-28 | 開始されました | Barclays | Equal Weight |
| 2025-11-04 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-04-01 | 再開されました | Chardan Capital Markets | Buy |
| 2024-12-10 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-02-29 | ダウングレード | Goldman | Buy → Neutral |
| 2023-12-19 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-03-17 | アップグレード | UBS | Neutral → Buy |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-05-21 | 開始されました | UBS | Neutral |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-04-01 | アップグレード | Mizuho | Neutral → Buy |
| 2021-01-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-24 | 開始されました | H.C. Wainwright | Buy |
| 2020-11-11 | 開始されました | Berenberg | Buy |
| 2020-11-09 | 開始されました | Jefferies | Buy |
| 2020-11-04 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-08-25 | 開始されました | Raymond James | Strong Buy |
| 2020-07-31 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-06-25 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | 開始されました | Cowen | Outperform |
| 2019-12-03 | 開始されました | Goldman | Buy |
| 2019-11-05 | 開始されました | Credit Suisse | Outperform |
| 2019-10-11 | 開始されました | Stifel | Buy |
| 2019-09-25 | 開始されました | Bernstein | Outperform |
| 2019-09-12 | 開始されました | Mizuho | Buy |
| 2019-07-30 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-07-08 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-04-12 | 開始されました | Piper Jaffray | Overweight |
| 2019-03-29 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Uniqure Nv (QURE) 最新ニュース
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $50 - Moomoo
FMR LLC lists 1.74M UNIQURE shares (2.8%) — UNIQURE (NASDAQ: QURE) - Stock Titan
Transcript: uniQure Q1 2026 Earnings Conference Call - Sahm
Uniqure NV at TD Cowen Healthcare Conference Transcript - GuruFocus
uniQure Q1 Earnings Call Highlights - Yahoo Finance
MSN Money - MSN
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Announces Target Price $28 - Moomoo
UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
UniQure Shares Fall After Q1 Loss Widens - marketscreener.com
UniQure 1Q Loss/Shr 85c >QURE - Moomoo
uniQure Releases Q1 2026 Financial Results - AlphaStreet
Uniqure NV reports results for the quarter ended March 31Earnings Summary - TradingView
uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings Flash (QURE) UniQure Posts Q1 Net Loss $0.85 a Share, vs. FactSet Est of $0.85 Loss - marketscreener.com
Earnings Flash (QURE) uniQure N.V. Reports Q1 Revenue $3.6M, vs. FactSet Est of $5.2M - marketscreener.com
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates - The Manila Times
UniQure: Q1 Earnings Snapshot - Barchart.com
uniQure N.V. 1Q 2026: Revenue $3.56M, Net income ($53.54M), EPS ($0.85) — 10-Q Summary - TradingView
[10-Q] uniQure N.V. Quarterly Earnings Report - Stock Titan
uniQure targets UK filing for AMT-130 as FDA seeks new trial plan - Stock Titan
uniQure (NASDAQ: QURE) Q1 2026 loss widens, holds $586.6M cash runway - Stock Titan
uniQure’s AMT-130 Regulatory Progress Sharpens Huntington’s Disease Investment Case - Yahoo Finance
US-listed shares of uniQure NV rise nearly 20% - marketscreener.com
UniQure plummets as FDA calls for phase 3 trial for Huntington's asset AMT-130 - MSN
Jennison Associates LLC Boosts Stake in uniQure N.V. $QURE - MarketBeat
uniQure advances AMT-130 toward UK marketing approval - The Globe and Mail
Update: UniQure Shares Rise After Firm Plans to Submit UK Marketing Application for Huntington's Disease Treatment - 富途牛牛
symbol__ Stock Quote Price and Forecast - CNN
uniQure (QURE) Shares Surge 22% on Positive Regulatory News for AMT-130 - GuruFocus
uniQure NV | SCHEDULE 13G/A: Others - Moomoo
UniQure Plans to Submit UK Marketing Authorization Application for Huntington's Disease Treatment - Moomoo
uniQure stock rises after regulatory updates (QURE:NASDAQ) - Seeking Alpha
UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy - BioPharma Dive
uniQure (NASDAQ:QURE) Shares Gap UpHere's Why - MarketBeat
uniQure plans UK filing for Huntington’s gene therapy AMT-130 By Investing.com - Investing.com India
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
uniQure meets with UK MHRA on AMT-130 for Huntington’s disease - The Pharma Letter
Aberdeen Group (QURE) reports 5.31M shares, 8.49% stake | Schedule 13G/A - Stock Titan
uniQure plans UK filing for Huntington’s gene therapy AMT-130 - Investing.com
uniQure NV | 8-K: Current report - Moomoo
AMT-130 Huntington’s gene therapy nears UK filing for uniQure (NASDAQ: QURE) - Stock Titan
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease - Yahoo Finance
Earnings Preview: UniQure NV to Report Financial Results Pre-market on May 05 - 富途牛牛
QURE stock crashes 32% in a week: Here's what you should know - MSN
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $70 - Moomoo
uniQure N.V. (NASDAQ:QURE) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
UniQure used 'distorted comparison' in Huntington's asset trial: FDA official - MSN
UniQure surges following departure of key FDA official - MSN
UniQure to Announce First Quarter 2026 Financial Results - marketscreener.com
Before the bell, uniQure posts Q1 numbers and takes questions May 5 - Stock Titan
uniQure to Announce First Quarter 2026 Financial Results - Sahm
Uniqure Nv (QURE) 財務データ
収益
当期純利益
現金流量
EPS
1.77%
0.25%
大文字化:
|
ボリューム (24 時間):